Discontinued — last reported Q2 '25
UnitedHealth Group Redeemable NCI decreased by 1.6% to $4.24B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 7.2%, from $4.57B to $4.24B. Over 4 years (FY 2020 to FY 2024), Redeemable NCI shows an upward trend with a 18.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase indicates a potential future cash outflow obligation, which could impact liquidity.
This represents equity interests in subsidiaries held by third parties that have redemption features, allowing the holde...
Common in companies with complex joint ventures or partially owned subsidiaries.
redeemable_noncontrolling_interests| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.30B | $1.37B | $1.43B | $1.52B | -$3.10B | $3.10B | $4.90B | $130.00M | $113.00M | $121.00M | $4.50B | $4.55B | $4.56B | $4.57B | $4.32B | $4.36B | $4.32B | $4.24B |
| QoQ Change | — | +5.7% | +4.4% | +5.9% | -304.1% | +200.1% | +57.8% | -97.3% | -13.1% | +7.1% | >999% | +1.1% | +0.2% | +0.4% | -5.5% | +0.8% | -1.0% | -1.6% |
| YoY Change | — | — | — | — | -338.7% | +126.1% | +241.5% | -91.4% | +103.6% | -96.1% | -8.1% | >999% | >999% | >999% | -3.9% | -4.2% | -5.3% | -7.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.